| abstract |
Disclosed is a compound represented by formula (1). The compound is a novel imidazolium derivative having an excellent antagonistic activity on a muscarinic M3 receptor and having excellent effectiveness, long-lasting efficacy and safety. The compound is a prophylactic or therapeutic agent for various diseases associated with airflow obstruction, such as chronic bronchial asthma, chronic obstructive pulmonary disease (COPD), asthma, chronic airway obstruction, fibroid lung, pulmonary emphysema, diffuse panbronchiolitis, bronchiectasis, idiopathic interstitial pneumonia and rhinitis. |